Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study

By sjmartinez • May 18, 2025

Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H, Angel B, Li Q, Chen X, Paller AS. Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study. J Am Acad Dermatol. 2025 May 14:S0190-9622(25)02124-3. doi: 10.1016/j.jaad.2025.05.1385. Epub ahead of print. PMID: 40378883.

Tags: atopic dermatitis, children, Dermatology, eczema, efficacy, JAK inhibitor, Janus kinase, pediatric, phase 3, Publications, randomized, ruxolitinib cream, safety, topical

Patient-Reported Outcomes by Baseline Body Surface Area Involvement Among Individuals Initiating Biologic Therapy: Results from the CorEvitas Psoriasis Registry

Armstrong AW, Feldman SR, Fitzgerald T, Alkousakis T, Sima A, Li A, Kang HJ, Main SI, Khattri S, Stein Gold L. Patient-Reported Outcomes by Baseline[...]

Biologic Mechanisms Underlying the Heterogeneous Response to Tight Glycemic Control among Differentially Inflamed Patients in the HALF-PINT Trial

Zinter MS, Taylor CS, Markovic D, Pellegrini M, Wong K, Balliu B, Gala KP, Asaro LA, Nadkarni VM, McQuillen PS, Vangala SS, Sinha P, Matthay[...]

Cutaneous manifestation of metastatic papillary thyroid carcinoma

Peng D, Dong E, Martinez D, Kang Y, Wong D, Holland V. Cutaneous manifestation of metastatic papillary thyroid carcinoma. JAAD Case Rep. 2025 Apr 11;60:129-131.[...]